This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Small-Cap Winners & Losers

Small stocks underperformed the broader market for the second straight session Thursday even as several companies rode high on various good news.

One of the day's best performers was Dusa Pharmaceuticals (DUSA), lately rocketing 57% in extremely heavy trading after the Food and Drug Administration granted "orphan drug" status to Levulan, the Wilmington, Mass., biotech's proposed therapy for esophageal dysplasia. The disease sometimes occurs in patients with Barrett's esophagus and is a high-risk possible precursor to esophageal cancer.

Orphan drug designation, given to promising drugs for treatment of rare diseases, allows for seven years of marketing exclusivity on FDA approval as well as possible grants and tax incentives during the developmental stage. Dusa shares surged $1.58 to $4.35.

Nextar Broadcasting (NXST - Get Report) also came out on top amid news it's considering selling itself, having retained Goldman Sachs to review this and other strategic alternatives. The Irving, Texas, TV broadcaster surged 20.1% to $13.08.

Massachusetts-based TechTarget (TTGT - Get Report), which operates a network of information-technology-products Web sites, jumped 16% to $15.08 following its 7.7-million-share initial public offering.

A couple of small names meanwhile fired up on positive analyst calls. Information-technology company Stanley (SXE - Get Report) leapt 9.7% to $17.71 after Wachovia upped it to outperform on the heels of impressive fiscal fourth-quarter results, and Lehman Brothers began coverage on Input/Output (IO - Get Report) with an overweight rating. The company, which sells seismic products and services to the oil-and-gas industry, recently added 3.4% to $14.23.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GERN $2.78 -1.90%
IO $9.06 0.33%
NXST $53.21 -1.60%
TTGT $7.65 -0.13%
SXE $2.19 5.30%


Chart of I:DJI
DOW 17,704.41 -46.50 -0.26%
S&P 500 2,056.36 -7.01 -0.34%
NASDAQ 4,745.3110 -17.9130 -0.38%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs